Illumina Expands Use of HiSeq X™ Sequencing System to Include Non-Human Species
October 06 2015 - 6:30AM
Business Wire
Illumina, Inc. (NASDAQ:ILMN) today announced it has
expanded the rights of use for the HiSeq X Sequencing System to
allow customers to perform whole-genome sequencing of non-human
species. The updated rights of use will take effect immediately for
existing customers of the HiSeq X Ten and HiSeq X Five, and will
apply to all new customers of the sequencing systems.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20151006005360/en/
HiSeq X™ Ten (Photo: Business Wire)
Driven by the world’s first $1,000 human genome and significant
demand for population-scale sequencing, more than 125,000 human
whole-genome samples have been sequenced on the platform since its
release in January 2014. The updated rights of use will allow for
market expansion and population-scale sequencing of non-human
species in a variety of markets, including plants and livestock in
agricultural research and model organisms in pharmaceutical
research. Previously, it has been cost prohibitive to sequence
non-human genomes at high coverage.
"The Wellcome Trust Sanger Institute is excited to be able to
sequence non-human genomes on the HiSeq X Platform,” said Emma
Millican, Director of Scientific Operations. “Understanding the
genetics and biological processes of non-human organisms is a major
area of focus for the Sanger Institute and this update will enable
large-scale whole-genome sequencing projects, important for public
health, that otherwise would not have happened. The Sanger
Institute plans to extend whole-genome population sequencing to
many more medically relevant organisms in the future.”
“Market adoption of the HiSeq X system for population-scale
studies has exceeded our expectations and we are excited for new
and existing customers to take their research to new heights,” said
Francis deSouza, President of Illumina. “With its ultrahigh
throughput and unprecedented price point per genome, the HiSeq X
system now provides customers with an opportunity to reshape the
economics and scale of whole-genome sequencing beyond the human
species.”
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
Forward-Looking Statements
This release may contain forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151006005360/en/
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243rchambers@illumina.comorMedia:Tina Amirkiai,
858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2024 to May 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From May 2023 to May 2024